Full-Time

Group Leader

Analytical Development

Posted on 3/22/2024

Vaxcyte

Vaxcyte

201-500 employees

Develops vaccines for bacterial infections

Compensation Overview

$150k - $174k/yr

+ Equity Component + Comprehensive Benefits

Senior, Expert

San Carlos, CA, USA

Category
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • PhD in Chemistry, Analytical Chemistry, Biochemistry, or related field with 8+ years relevant industry experience; MS or BS with 15+ years of industry experience in Pharma/ Biotech industry required.
  • Proven leadership skills.
  • Outstanding organization and planning skills.
  • Must be a strong scientific leader who can guide scientists with clear goals of developing analytical methods, and critically and skillfully review and assess analytical methods under development. May need to provide direction for troubleshooting various issues during method development.
  • Proven track record of analytical development leadership for biologics and small molecules, experience with vaccines, carbohydrate, or conjugates is a plus.
  • Extensive expertise in U/HPLC, CE, SDS-PAGE, mass spectrometry, and other analytical technologies as applied to protein analytical method development, trouble shooting and validation for GMP release and stability testing.
  • Knowledge of capillary electrophoresis and/or experience in use of such would be a plus.
  • Experience in protein, carbohydrate, and conjugates analysis is highly desired, for example hands on experience and theoretical understanding of HPAEC-PAD, HPLC/UV/FLD, SEC-LC, SEC-MALS, and colorimetric assays are highly desired.
  • Attention to detail and excellent skills in record keeping / documentation. Critical thinking and ability to analyze data.
  • Strong interpersonal skills: ability to communicate effectively both verbally and in written formats.
  • Ability to work with minimum supervision in a fast-paced, cross-functional environment and collaborate effectively with other team members. Eagerness and ability to learn and understand new concepts with ease.
Responsibilities
  • Manage R&D ADQC stability programs, such as but not limited to, providing sampling volume forecast, coordinating with stability group on stability set-down and monitoring each stability pull-point.
  • Manage in-house routine testing, such as stability and release testing, characterization, in-process samples analysis and reference standard qualification. Responsible for the overall quality and compliance of all the testing.
  • Provide technical direction, mentorship and coaching to the analytical development team.
  • Lead the design and interpretation of experiments to analyze raw materials.
  • Keep accurate and detailed records of experiments in laboratory notebooks.
  • Summarize data and communicate to cross functional team such as stability, PD and PM.
  • Represent ADQC to attend X-Functional lab operation alignment meeting led by facility.
  • Work within a team environment and provide support to further team objectives.
Desired Qualifications
  • Experience with vaccines, carbohydrate, or conjugates is a plus.
  • Knowledge of capillary electrophoresis and/or experience in use of such would be a plus.

Vaxcyte develops vaccines aimed at preventing bacterial infections, focusing on diseases like invasive pneumococcal disease, Group A Strep, periodontitis, and Shigella. Their lead product, VAX-24, is a pneumococcal conjugate vaccine that targets 24 strains of the Streptococcus pneumoniae bacteria and has received Breakthrough Therapy designation from the FDA. Vaxcyte utilizes advanced chemistry and a proprietary cell-free protein synthesis platform, XpressCF™, to create vaccines that can effectively bypass the complex defenses of bacteria while still provoking an immune response. This method sets them apart from traditional cell-based vaccine production. The company's goal is to develop and commercialize broad-spectrum vaccines to address significant health threats posed by bacterial infections.

Company Size

201-500

Company Stage

IPO

Headquarters

Foster City, California

Founded

2013

Simplify Jobs

Simplify's Take

What believers are saying

  • Vaxcyte's VAX-24 has FDA Breakthrough Therapy designation for pneumococcal disease prevention.
  • Recent $1.5 billion public offering boosts Vaxcyte's financial resources for vaccine development.
  • Growing antibiotic resistance increases demand for Vaxcyte's novel bacterial vaccines.

What critics are saying

  • Competition from mRNA vaccine developers like Moderna and BioNTech is intense.
  • Supply chain vulnerabilities could disrupt Vaxcyte's proprietary XpressCF™ platform.
  • Emerging bacterial strains may not be covered by Vaxcyte's current vaccine candidates.

What makes Vaxcyte unique

  • Vaxcyte uses a proprietary cell-free protein synthesis platform, XpressCF™, for vaccine development.
  • Their lead product, VAX-24, targets 24 strains of Streptococcus pneumoniae.
  • Vaxcyte's vaccines aim to combat bacterial infections, including pneumococcal disease and Group A Strep.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Stock Options

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

2%

2 year growth

1%
Clinical Trial Vanguard
Mar 31st, 2025
Vaxcyte Announces Positive VAX-24 Infant Phase 2 Results

Vaxcyte aims to develop superior vaccines against bacterial diseases, utilizing advanced synthetic techniques like their XpressCF(TM) cell-free protein synthesis platform.

MarketBeat
Oct 5th, 2024
Clearbridge Investments LLC Makes New $14.06 Million Investment in Vaxcyte, Inc. (NASDAQ:PCVX)

Clearbridge Investments LLC makes new $14.06 million investment in Vaxcyte, Inc. (NASDAQ:PCVX).

Bizjournals
Sep 20th, 2024
Winner, Public Company, Small: Andrew Guggenhime, Vaxcyte Inc.

In the early weeks of the Covid-19 pandemic, Andrew Guggenhime joined San Carlos-based Vaxcyte Inc. as chief financial officer and chief operating officer, drawn by the company's mission to develop vaccines to prevent and treat infectious bacterial diseases.

Yahoo Finance
Sep 9th, 2024
Vaxcyte Announces Pricing of $1.3 Billion Public Offering

SAN CARLOS, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the pricing of an underwritten public offering of common stock and pre-funded warrants. Vaxcyte is selling 10,194,175 shares of common stock and pre-funded warrants to purchase 2,427,184 shares of common stock in the offering. The shares of common stock

Vaxcyte
Sep 6th, 2024
Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Vaxcyte announces closing of $1.5 billion public offering including full exercise of underwriters' option to purchase additional shares.

INACTIVE